KDC-MN-1325 – Kodiac biolabs

Our opinion on this compoundSingle-lab provenance

45/100

Clever BBB-penetrant Semax variant with a real pharmacokinetic rationale and near-zero Western evidence base

Look, Adamax is a genuinely clever piece of peptide engineering. Taking Semax, the ACTH(4-10) analog that Russian investigators have studied for decades, and N-terminally conjugating an adamantyl group to boost lipophilicity by roughly three log units – that’s not incremental chemistry. The result is a compound that theoretically crosses the blood-brain barrier via oral and parenteral routes, something the parent Semax simply cannot do reliably outside the intranasal window. For a researcher who wants to study ACTH-derived heptapeptide biology without the intranasal constraint, this is the obvious tool to reach for.

The mechanism story is Semax’s mechanism story, and that’s both a strength and a limitation. BDNF and NGF transcriptional upregulation in cortex and hippocampus, pro-cognitive effects in passive avoidance and Morris water maze models, neuroprotection in middle cerebral artery occlusion preparations – these are real, reproducible preclinical outputs from the Semax literature. Adamax inherits that mechanistic rationale. What it doesn’t inherit is the evidence mass. The published record for Adamax specifically is thin, concentrated in Russian-language output from the Institute of Molecular Genetics RAS, and there’s no meaningful Western replication. Thats the core problem.

Honestly, this is the Epitalon situation in a different peptide class. Single-consortium literature, difficult-to-verify methodology, no independent replication. The parent compound has a more credible preclinical record and even some Russian clinical use. Adamax’s advantage is pharmacokinetic engineering, not additional biological validation. So we’re scoring the improvement in delivery without being able to confirm the improvement in outcomes.

What we like: the adamantyl modification is a real structural rationale, not hand-waving. Increased lipophilicity is measurable. The extended CSF half-life claim is mechanistically plausible. If you’re running a BDNF/NGF stimulation program and need a non-intranasal tool in that peptide family, Adamax fills a specific gap that nothing else fills cleanly. The BBB-penetrant adamantyl conjugation strategy also has broader relevance as a delivery concept worth watching in peptide pharmacology.

What we don’t like: the sourcing reality is uncomfortable. This compound exists in the research-grade peptide gray market with essentially no quality standard tied to published Western pharmacology. The reduced aqueous solubility means DMSO stocks for most in vitro work, which adds a variable you have to account for. And the absence of any clinical development signal, even modest early-stage work, means the bench-to-clinic arrow is pointing nowhere right now. A score of 45 reflects a compound worth tracking if you’re already in the ACTH-peptide space, but not a priority for investigators without a specific reason to be here.

Novelty: 62
Mechanism promise: 48
In-category differentiation: 55
Evidence quality: 22
Translational signal: 25
Research bench value: 45

Rationale Adamantyl modification of Semax is genuinely novel delivery engineering with plausible mechanism inheritance, but the published record is single-consortium Russian-language literature with no Western replication and no human signal for Adamax specifically; evidence and translational scores drag the overall to the mid-40s despite the structural novelty.

Synthetic melanocortin-derived nootropic peptide with dual N-acetyl and C-terminal adamantane modifications for enhanced blood-brain barrier permeability and neurotrophic factor modulation

A next-generation ACTH(4-10) analog engineered from Semax with N-terminal acetylation and C-terminal adamantylglycine amidation, designed to extend plasma half-life and central nervous system bioavailability while preserving the parent compound’s neurotrophic, neuroprotective, and monoaminergic pharmacology.

Abstract

Adamax (N-Acetyl Semax-Adamantane; Ac-MEHFPGP-AdaGly-NH2) is a synthetic nonapeptide research compound derived from Semax, the Russian-developed ACTH(4-10) analog approved in the Russian Federation for the treatment of ischemic stroke and cognitive impairment. The compound incorporates two structural modifications to the Semax backbone (Met-Glu-His-Phe-Pro-Gly-Pro): an N-terminal acetyl group that shields the peptide from aminopeptidase degradation and a C-terminal adamantylglycine amide that increases lipophilicity, enhances blood-brain barrier penetration, and confers resistance to carboxypeptidase cleavage. These modifications extend the effective half-life from approximately 30 to 60 minutes (Semax) to an estimated 8 to 10 hours and increase central nervous system bioavailability, enabling single daily dosing protocols in research applications.

The pharmacological rationale for Adamax rests on the established molecular pharmacology of its parent compound Semax and on the broader adamantane medicinal chemistry literature. Semax activates brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) signaling in the hippocampus and basal forebrain, modulates melanocortin-3 and melanocortin-4 receptor (MC3R/MC4R) activity in cortical and hypothalamic circuits, and enhances dopaminergic and serotonergic neurotransmission in the striatum and prefrontal cortex [1, 2, 3]. Adamax preserves this multi-target pharmacology while the adamantane cage, a rigid tricyclo[3.3.1.1(3,7)]decane hydrocarbon scaffold shared with the FDA-approved drugs amantadine and memantine, confers the lipophilicity necessary for passive transcellular blood-brain barrier transit and reduces the susceptibility of the C-terminus to exopeptidase degradation [4, 5].

Adamax does not have independent, peer-reviewed clinical or preclinical pharmacology publications indexed in PubMed or comparable biomedical databases as of the date of this monograph. All mechanistic characterization is inferred from the extensive published literature on Semax (over 300 publications, predominantly in Russian-language journals with a growing English-language subset), from the P21 (P021) adamantane-modified neurotrophic peptide literature, and from the structure-activity relationships of the ACTH(4-10) melanocortin fragment class. The compound is sold as a research-grade preparation by multiple peptide suppliers and has been identified as a designer peptide in border seizures by the New Zealand Medicines and Medical Devices Safety Authority [6]. It is not approved by any regulatory agency for therapeutic use. Investigators should treat all pharmacological claims as extrapolations from parent-compound data until independent Adamax-specific studies are published. This monograph reviews the chemistry, structural rationale, inferred mechanism of action, pharmacokinetic considerations, the parent-compound evidence base, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, the safety signal profile, and a comparative assessment of five related nootropic peptide compounds (Semax, N-Acetyl Semax Amidate, P21, Selank, Noopept) against Adamax on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1325Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1325

Adamax

Abstract

Read the full monograph